FOXO3 and left ventricular hypertrophy: Therefore, it can be inferred that the molecular processes responsible for the development of left ventricular hypertrophy (LVH) in chronic kidney disease (CKD) are not influenced by FOXO3, ERK1/2, AMPK, and AKT/mTOR-mediated pathways.